期刊文献+

典型国家疗效协议研究及启示 被引量:2

Study and Inspiration of Efficacy Agreements in Typical Countries
下载PDF
导出
摘要 基于我国医保药品谈判的现状与存在问题,主要研究了典型发达国家的药品疗效协议,包括基本含义、协议品种、协议内容(观察指标与周期、数据收集、响应与支付),在此基础上,提出建议:提高我国医保药品谈判的全面性与科学性、建立专业的评估体系与机构。 Based on the status quo and existing problems of China's medical insurance drug negotiations,the drug efficacy agreements in typical developed countries are studied,including the basic meaning,the types of agreements,and the content of the agreements(observation indicators and cycles,data collection,response and payment).This paper put forward suggestions to improve the comprehensiveness and scientificity of China's medical insurance drug negotiations and establishment of a professional evaluation system and institutions.
作者 赵华婷 颜建周 邵蓉 ZHAO Hua-ting;YAN Jian-zhou;SHAO Rong(National Pharmaceutical Policy and Pharmaceutical Industry Economic Research Center,China Pharmaceutical University,Nanjing Jiangsu 211198,China)
出处 《卫生经济研究》 北大核心 2020年第4期50-53,共4页
基金 2015年度国家社科基金重大项目(第二批)“我国创新药物政策环境研究”基金资助(15ZDB167) 中国药科大学“双一流”学科创新团队建设项目支持(CPU2018GY39)。
关键词 医保 药品谈判 疗效协议 风险共担 medical insurance drug negotiation efficacy agreement risk sharing
  • 相关文献

参考文献3

二级参考文献18

  • 1何建志.全民健康保险价量协议法律问题分析[J].台大法学论丛,2014,43(2):381-417.
  • 2de Pouvourville G. Risk-sharing agreements for innovative drugs[J]. The European Journal of Health E- conomics, 2006, 7(3): 155-157.
  • 3Ethgen O. Risk-sharing: The Need to Think Differently [EB/OL]. http://www.ispor.org/news/articles/ May -June2011/Risk -sharing -The -Need -to -Think - Differently.asp, 2011.
  • 4Adamski J, Godman B, et al. Risk sharing ar- rangements for pharmaceuticals: potential considera- tions and recommendations for European payers [J]. BMC health services research, 2010, 10(1): 153.
  • 5Towse A, Garrison Jr L P. Can't get no satis- faction? Will pay for performance help? [J]. Pharma- coeconomics, 2010, 28(2): 93-102.
  • 6Klemp M, Frznsdal K B, Facey K. What princi- ples should govern the use of managed entry agree- ments? [J]. International journal of technology assess- merit in health care, 2011, 27(1): 77-83.
  • 7Carlson J J, Sullivan S D, Garrison L P, et al. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between heahhcare payers and manufacturers [J]. Health policy, 2010, 96(3): 179-190.
  • 8Garrison L P, Towse A, Briggs A, et al. Perfor- mance-based risk-sharing arrangements--good prac- tices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force [J]. Value in Health, 2013, 16(5): 703-719.
  • 9Morel T, Arickx F, Befrits G, et al. Reconciling uncertainty of costs and outcomes with the need for ac- cess to orphan medicinal products: a comparative study of managed entry agreements across seven European countries[J]. Orphanet J Rare Dis, 2013, 8: 198.
  • 10卫生福利部中央健康保险署.全民健康保险药物给付项目及支付标准[EB/OL].http://www.nhi.gov.tw/webdatgwebdata.aspx?menu=l7&menu_id=879&WD_ID=994&webdata_id=4295.2015-11-03.

共引文献16

同被引文献10

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部